BCMA-TACI DUAL SPECIFIC T CELL ENGAGER
HMBD-009 is our pioneering next-generation antibody program that targets both BCMA and TACI, proteins commonly overexpressed on tumor cells in multiple myeloma, the second most common hematologic malignancy and a leading cause of cancer deaths in the US.
Why BCMA and TACI?
HMBD-009 is our pioneering next-generation T cell engager program that targets both B cell maturation antigen (BCMA) and transmembrane activator and CAML interactor (TACI), proteins commonly overexpressed in multiple myeloma, the second most common hematologic malignancy and a leading cause of cancer deaths in the US.
BCMA and TACI both promote tumor cell survival in multiple myeloma. While BCMA has become a key treatment target for new experimental therapies, their long-term efficacy is hampered by the loss of BCMA from tumor cells over time, resulting in most patients relapsing.
Engineer with Precision
A new strategy with greater therapeutic potential is the co-targeting of both BCMA and TACI. But developing a monoclonal antibody that binds strongly and specifically to both these proteins is challenging as there is little overlap in their structures.
HMBD-009 is a unique T cell engager engineered to bind strongly and specifically to a critical yet elusive region shared by BCMA and TACI. Once bound, HMBD-009 engages with T cells and directs them to attack the tumor cells expressing BCMA and TACI. Preclinical studies demonstrate that HMBD-009 binding leads to the killing of tumor cells expressing BCMA and TACI.
American Association for Cancer Research 2021: Dual-specific antibodies that bind to BCMA and TACI (HMBD-009) enable better targeting of multiple myeloma in pre-clinical models.
Publications & Posters
AACR 2021: Dual-specific biotherapeutics targeting BCMA and TACI have the potential to overcome resistance mechanisms in multiple Myeloma
Hummingbird Bioscience Presents Pre-Clinical Data on its Next-Generation BCMA-TACI Dual-Specific T Cell Engager at 2021 AACR Annual Meeting
10 April 2021